About US
Contact us
-
Valeant scoops up Bausch + Lomb as it eyes $20B in revenuesAfter rumors of balked-at price tags and an in-the-making IPO, eye-care giant Bausch + Lomb will soon belong to Valeant Pharmaceuticals ($VRX) in exchange for $8.7 billion. Under the deal, expected2013/5/29
-
AstraZeneca bets up to $443M on Omthera lipid drugPipeline-starved AstraZeneca ($AZN) snapped up Omthera ($OMTH) in a deal worth up to $443 million, on hopes for the company's omega-3 cardio drug Epanova.2013/5/28
-
Drug therapies to inhibit Dkk1 function may limit arteriosclerotic disease, study findsDrug therapies designed to inhibit endothelial Dkk1 signalling could help limit arteriosclerotic disease to prevent the thickening and hardening of the arteries.Research published online by Arterioscl2013/5/28
-
FDA responds to one small piece of Avandia criticismThe FDA yesterday responded to a Forbes op-ed from Steven Nissen, Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, published earlier that day. In it, Nissen railed the F2013/5/27
-
AbbVie takes some heat for raising price of Niaspan after studies panned itWhen studies ofAbbVie'schloesterol drug Niaspan raised questions about its effectiveness, analysts suggested it would lose its blockbuster status. But in the face of falling sales, AbbVie'sformer par2013/5/27
-
Billionaires snap up former Merck Serono HQ for Geneva biotech hotspotTwo Swiss billionaires--Ernesto Bertarelli and Hansjörg Wyss--have joined forces to buy out the former Merck Serono facility in Geneva, with ambitious plans to create a major collaboration on di2013/5/23
-
CFDA issues The Second Drug Quality Announcement of 2013China Food and Drug Administration (CFDA) issued on May 16, 2013 the Second Drug Quality Announcement of 2013, and released the quality sampling and testing results of 11 national essential drugs and2013/5/23
-
Impax calls on former Teva, Watson execs to confront FDA issuesHaving failed so far to get its extended-release Parkinson's drug Rytary to market, Impax Laboratories ($IPXL) is turning to asking three big-name specialists what it should do. The Hayward, CA dru2013/5/22
-
Vermont passes assisted-suicide law, with drug-dispensing safeguardsVermont officially became the fourth state to allow physician-assisted suicide. The law includes safeguards, including requirements that terminally ill patients ask for the requisite drugs three time2013/5/22
-
GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cutsIndia's skeptical patent regime is only one of pharma's worries in the country. New price controls are on their way, and brokerage house HSBC has identified which companies are most likely to suffer2013/5/21